A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT02389985
- Locations
- 🇺🇸
University of Virginia Health System, Charlottesville, Virginia, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Oklahoma / Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
Phase 1/2a Dose-Escalation Study of CRLX301 in Patients With Advanced Solid Tumors
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 42
- Registration Number
- NCT02380677
- Locations
- 🇺🇸
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸MD Anderson, Houston, Texas, United States
CRLX101(NLG207) in Combination With Bevacizumab for Metastatic Renal Cell Carcinoma (mRCC) Versus Standard of Care (SOC)
- Conditions
- Metastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 115
- Registration Number
- NCT02187302
- Locations
- 🇺🇸
University of California San Diego, La Jolla, California, United States
🇺🇸Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Texas Oncology, Dallas, Dallas, Texas, United States
Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic AdenocarcinomaMetastatic Pancreatic Cancer
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 157
- Registration Number
- NCT02077881
- Locations
- 🇺🇸
University of Kentucy, Lexington, Kentucky, United States
🇺🇸Greenville Health Systems, Greenville, South Carolina, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma
- Conditions
- Metastatic MelanomaStage III MelanomaStage IV Melanoma
- Interventions
- First Posted Date
- 2014-02-27
- Last Posted Date
- 2020-06-05
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 132
- Registration Number
- NCT02073123
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
🇺🇸Penn State Hershey Cancer Institue, Hershey, Pennsylvania, United States
🇺🇸Augusta University, Augusta, Georgia, United States
Immunotherapy Study for Patients With Stage IV Melanoma
- Conditions
- Stage IV MelanomaMetastatic Melanoma
- Interventions
- First Posted Date
- 2014-02-04
- Last Posted Date
- 2023-04-18
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 47
- Registration Number
- NCT02054520
- Locations
- 🇺🇸
University of Tennessee Medical Center, Knoxville, Tennessee, United States
🇺🇸University of Kansas Cancer Center, Westwood, Kansas, United States
🇺🇸Oncology Specialists, Niles, Illinois, United States
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
- Conditions
- GliomaGliosarcomaGlioblastoma MultiformeMalignant Brain Tumor
- Interventions
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2024-03-27
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 160
- Registration Number
- NCT02052648
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸University Cancer and Blood Center, Athens, Georgia, United States
🇺🇸UC Irvine Chao Family Comprehensive Cancer Center, Orange, California, United States
Immunotherapy Study for Metastatic Renal Cell Cancer
- Conditions
- Metastatic Kidney CancerMetastatic Clear-cell Renal CancerRefractory Renal Cell CarcinomaRecurrent Renal Cell CarcinomaMetastatic Renal Cell Carcinoma
- Interventions
- Biological: HyperAcute®-Renal (HAR) Immunotherapy
- First Posted Date
- 2014-01-14
- Last Posted Date
- 2022-04-06
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 18
- Registration Number
- NCT02035358
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
🇺🇸John Hopkins University, Baltimore, Maryland, United States
🇺🇸Univeristy of Utah, Salt Lake City, Utah, United States
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
- Conditions
- Pancreatic Carcinoma Non-resectableLocally Advanced Malignant NeoplasmPancreatic Cancer
- Interventions
- Radiation: 5-FU ChemoradiationBiological: Algenpantucel-L Immunotherapy
- First Posted Date
- 2013-04-19
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 302
- Registration Number
- NCT01836432
- Locations
- 🇺🇸
Sutter Institute for Medical Research, Sacramento, California, United States
🇺🇸USF Tampa General, Tampa, Florida, United States
🇺🇸Indiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
- Conditions
- Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2013-02-15
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- NewLink Genetics Corporation
- Target Recruit Count
- 169
- Registration Number
- NCT01792050
- Locations
- 🇵🇱
Research Site, Warsaw, Poland
🇺🇸University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States